Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of SAR441566 in adults with moderate to severe Crohn's disease
CTR20250072Phase 2Active
- Sponsor
- Sanofi
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of balinatunfib in Crohn's disease, sponsored by Sanofi. Started Jun 2025; status: active.
02
Drugs
balinatunfib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20250072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250072.